{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:38:03Z","timestamp":1792777083129,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.kint.2026.08.021","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:16:32Z","timestamp":1790205392000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria"],"prefix":"10.1016","author":[{"given":"Matthew R.","family":"Weir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbani","family":"Bhaduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kooienga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Kopjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Novin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.08.021_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: core curriculum 2019","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.021_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.kint.2026.08.021_bib4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.115.05694","article-title":"Prevalence of apparent therapy-resistant hypertension and its effect on outcome in patients with chronic kidney disease","volume":"66","author":"de Beus","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2026.08.021_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2026.08.021_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.08.021_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030142","article-title":"Adverse effects of aldosterone: beyond blood pressure","volume":"13","author":"Brown","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.kint.2026.08.021_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11906-010-0116-4","article-title":"Aldosterone in the pathogenesis of chronic kidney disease and proteinuria","volume":"12","author":"Lu","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2026.08.021_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.021_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.08.021_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.08.021_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2026.08.021_bib13","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.021_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.kint.2026.08.021_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.kint.2026.08.021_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.08.021_bib17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.021_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.08.021_bib19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.021_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254950","article-title":"Cost-effectiveness of artificial intelligence monitoring for active tuberculosis treatment: a modeling study","volume":"16","author":"Salcedo","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.08.021_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102875","article-title":"Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta-analysis","volume":"49","author":"Siddiqui","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.kint.2026.08.021_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.021_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/pst.1638","article-title":"A recommended analysis for 2 \u00d7 2 crossover trials with baseline measurements","volume":"13","author":"Mehrotra","year":"2014","journal-title":"Pharm Stat"},{"key":"10.1016\/j.kint.2026.08.021_bib24","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1002\/sim.7081","article-title":"Improved power in crossover designs through linear combinations of baselines","volume":"35","author":"Jemielita","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2026.08.021_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4097\/kja.21165","article-title":"Considerations for crossover design in clinical study","volume":"74","author":"Lim","year":"2021","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.kint.2026.08.021_bib26","unstructured":"Shen D, Luz Z. Estimate carryover effect in clinical trial crossover designs. Poster Presented at: Pharmaceutical Industry SAS\u00ae Users Group 2006 Conference. May 21-24, 2006; Bonita Springs, FL. Poster PO16."},{"key":"10.1016\/j.kint.2026.08.021_bib27","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2026.08.021_bib28","article-title":"Effect of blood pressure control on cardiovascular events in patients with chronic kidney disease: a systematic review","volume":"17","author":"Ahmed","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.kint.2026.08.021_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.12104","article-title":"Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease","volume":"76","author":"Cravedi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2026.08.021_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.ajkd.2014.02.020","article-title":"Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.021_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2026.08.021_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.021_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.021_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2026.08.021_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.119.14659","article-title":"Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: a post hoc analysis of the SPRINT and ACCORD-BP randomized controlled trials","volume":"75","author":"Collard","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2026.08.021_bib36","first-page":"726","article-title":"Lorundrostat efficacy and safety in uncontrolled hypertension: reply","volume":"393","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.021_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105835","article-title":"Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management","volume":"172","author":"Hundemer","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2026.08.021_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100943","article-title":"Efficacy of mineralocorticoid receptor antagonists on kidney and cardiovascular outcomes in patients with chronic kidney disease: an umbrella review","volume":"7","author":"Amornritvanich","year":"2025","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2026.08.021_bib39","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2026.08.021_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.08.021_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","article-title":"Inhibition of aldosterone synthase: does this offer advantages compared with the blockade of mineralocorticoid receptors?","volume":"46","author":"Ando","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2026.08.021_bib42","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kint.2026.08.021_bib43","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.15420\/cfr.2025.09","article-title":"The emerging role of aldosterone synthase inhibitors in overcoming renin\u2013angiotensin\u2013aldosterone system therapy limitations: a narrative review","volume":"11","author":"Patel","year":"2025","journal-title":"Cardiac Failure Review"},{"key":"10.1016\/j.kint.2026.08.021_bib44","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41440-022-00913-4","article-title":"Aldosterone breakthrough from a pharmacological perspective","volume":"45","author":"Mogi","year":"2022","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2026.08.021_bib45","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2026.08.021_bib46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1210\/jcem.87.2.7980","article-title":"Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans","volume":"87","author":"Sawathiparnich","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2026.08.021_bib47","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.08.021_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2026.08.021_bib49","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.08.021_bib50","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s00125-019-4948-4","article-title":"The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study","volume":"62","author":"Oshima","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.08.021_bib51","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:47:20Z","timestamp":1792774040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826008082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S0085253826008082"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.08.021","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}